GeneQuantum Healthcare
GeneQuantum is a global leader in the ADC field, renowned for leading the advancement of enzymatic site-specific conjugation technologies. GQ has successfully pioneered two innovative enzymatic site-specific conjugation technologies: iLDC and iGDC. These technologies serve as the foundation of our robust ADC drug development platform, covering the entire spectrum from initial design of ADC drug to seamless full-scale commercial production. Distinguishing itself from conventional ADC drugs, those fortified with GQ’s technology offer a multitude of benefits including exceptional product homogeneity, elevated process quality, and enhanced metabolic stability.
